Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1E,4Z,6E)-1,7-bis(3-bromo-4-hydroxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
-
cinnamoyl-II
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
BDMC
(1E,4Z,6E)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
DMC
(2-ethoxypropoxy)benzene
-
-
(2E)-2-(ethoxycarbonyl)heptadec-2-enoic acid
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
(2E)-2-(ethoxycarbonyl)hexadec-2-enoic acid
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
(2E)-2-acetylhexadec-2-enoic acid
-
-
(2E)-2-acetylpentadec-2-enoic acid
-
-
(2E,6E)-2,6-bis[(3,4-dihydroxyphenyl)methylidene]cyclohexan-1-one
89% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(3,5-dibromo-4-hydroxyphenyl)methylidene]cyclohexan-1-one
(2E,6E)-2,6-bis[(3-bromophenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(3-fluoro-4-hydroxyphenyl)methylidene]cyclohexan-1-one
6.3% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(4-hydroxy-3,5-dimethylphenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(4-hydroxy-3-iodophenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(4-hydroxy-3-methylphenyl)methylidene]cyclohexan-1-one
3.0% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(4-hydroxyphenyl)methylidene]cyclohexan-1-one
(2E,6E)-2,6-bis[(pyridin-3-yl)methylidene]cyclohexan-1-one
-
-
(2R)-2-[2-(4-[[(3-methyl-1-oxo-1,2-dihydrobenzo[f]quinazolin-9-yl)methyl]amino]phenyl)-2-oxoethyl]pentanedioic acid
-
(2R,3S)-4-methylidene-5-oxo-2-propyltetrahydrofuran-3-carboxylic acid
-
i.e. butyrolactone MB-3, a GCN5 inhibitor
(2S)-2-(5-[[(3-methyl-1-oxo-1,2-dihydrobenzo[f]quinazolin-9-yl)methyl]amino]-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid
ZINC36175770
(3-oxo-1,2-benzothiazol-2(3H)-yl)(phenyl)acetic acid
-
-
(3E,5E)-1-benzyl-3,5-bis[(3,4-dihydroxyphenyl)methylidene]piperidin-4-one
19.4% residual activity at 0.1 mM
(3E,5E)-3,5-bis[(3,4-dihydroxyphenyl)methylidene]-1-methylpiperidin-4-one
82.4% residual activity at 0.1 mM
(3E,5E)-3,5-bis[(3-bromo-4-hydroxyphenyl)methylidene]-4-oxopiperidin-1-ium
-
-
(3Z,5Z)-3,5-bis[(3-bromo-4-hydroxyphenyl)methylidene]thian-4-one
7.13% residual activity at 0.1 mM
(4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl) phenyl)phosphonic acid
-
(4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)phenyl)phosphonic acid
-
(4E)-2-(4-acetylphenyl)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
(5E)-1-(3-chloro-4-methylphenyl)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione
-
(E)-4-(2-(5,6-dimethylbenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(5-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(5-chlorobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(6-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-2-chloro-N,N-diethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-fluorobenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-methylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methoxyphenyl)benzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methylbenzyl)benzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-benzylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-phenylbenzenesulfonamide
(E)-N,N-diethyl-4-(2-(5-fluorobenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
(E)-N,N-diethyl-4-(2-(5-methoxybenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
(E)-N,N-diethyl-4-(2-(5-methylbenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
(NH4)2SO4
-
competitive against both acetyl-CoA and histones
1,1'-(1,4-phenylene)bis[3-(butylsulfanyl)pyrrolidine-2,5-dione]
-
-
1,3-dibenzyl-5-[(4-hydroxy-2,6-dimethylphenyl)methylidene]-1,3-diazinane-2,4,6-trione
-
-
1,3-dibenzyl-5-[(4-hydroxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
-
-
1,7-bis(3-bromo-4-hydroxyphenyl)-1,6-heptadiene-3,5-dione
-
-
1-(2-pentylphenyl)ethan-1-ol
-
-
1-(2-pentylphenyl)ethan-1-one
-
-
1-(4-(3-nitrophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
1-(4-(4-chlorophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
1-(S-coenzyme A)hex-5-ene
-
-
1-(S-coenzyme A)propan-2-one
-
-
1-benzyl-3,5-bis[(E)-3-bromo-4-hydroxybenzylidene]piperidin-4-one
81.6% residual activity at 0.1 mM
10-(benzyloxy)-2,3,11-trimethoxy-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium chloride
-
-
13,14 disulfoxyisogarcinol
-
LTK-19
14-isopropoxyisogarcinol
-
LTK-13
14-methoxyisogarcinol
-
LTK-14
2'-chloro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
2'-fluoro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
2'-methoxy-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
2,2-dimethyl-5-tetradecyl-1,3-dioxane-4,6-dione
-
-
2,2-dimethyl-5-tetradecylidene-1,3-dioxane-4,6-dione
-
-
2,3,11,12-tetramethoxy-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium methanesulfonate
-
-
2,3,11-trimethoxy-10-[(4-nitrophenyl)methoxy]-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
2,3-difluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(pyridin-2-yl)benzohydrazide
-
WM-1119
2,3-difluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2,4-difluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2,5-bis[(E)-3-bromo-4-hydroxybenzylidene]cyclopentan-1-one
41.2% residual activity at 0.1 mM
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
-
2,5-diphenylisothiazol-3(2H)-one
-
-
2,6-bis(3,4-dibromobenzylidene)cyclohexan-1-one
85.1% residual activity at 0.1 mM
2,6-bis(3-bromo-4-hydroxybenzylidene)cyclohexanone
2,6-bis(3-chloro-4-hydroxybenzylidene)cyclohexan-1-one
7.7% residual activity at 0.1 mM
2,6-bis(3-chloro-5-fluoro-4-hydroxybenzylidene)cyclohexan-1-one
41.1% residual activity at 0.1 mM
2,6-bis(4-hydroxy-3-iodobenzylidene)cyclohexan-1-one
5.8% residual activity at 0.1 mM
2,6-bis[(6-hydroxy-1,1'-biphenyl-3-yl)methylene]cyclohexan-1-one
92.2% residual activity at 0.1 mM
2,6-difluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-(1,3-benzothiazol-2-yl)-1,2-benzothiazol-3(2H)-one
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(3-methoxyphenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-(3-nitrophenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
2-(2-pyridyl)-isothiazol-3(2H)-one
-
-
2-(2-[[(1S)-3-(5-[[5-(3-carbamimidamidopropyl)-3,6-dioxopiperazin-2-yl]methyl]-2-hydroxyphenoxy)-1-carboxypropyl]amino]-2-oxoethyl)-2-hydroxybutanedioic acid
-
NK13650B
2-(3,5-difluoro-4-hydroxyphenyl)-4-((5-(4,5-dimethyl-2-(trifluoromethyl)phenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(3,5-difluoro-4-hydroxyphenyl)-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(3,5-difluoro-4-hydroxyphenyl)-5-methyl-4-((5-(2-(trifluoromethoxy)phenyl)furan-2-yl)methylene)-2,4-dihydro-3H-pyrazol-3-one
-
2-(3,5-difluoro-4-hydroxyphenyl)-5-methyl-4-((5-(3-oxo-2,3-dihydro-1H-inden-4-yl)furan-2-yl)methylene)-2,4-dihydro-3H-pyrazol-3-one
-
2-(3-chloro-4-fluorophenyl)isothiazol-3(2H)-one
-
2-(3-fluoro-5-(2-((2-fluorophenyl)sulfonyl)hydrazinecarbonyl)-phenyl)pyridine 1-Oxide
-
2-(3-methoxyphenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.007 mM with SK-N-SH cell
2-(3-oxo-1,2-benzothiazol-2(3H)-yl)-N-(1,3-thiazol-2-yl)acetamide
-
-
2-(3-pyridyl)-isothiazol-3(2H)-one
-
-
2-(4,6-dimethyl-3-oxo[1,2]thiazolo[5,4-b]pyridin-2(3H)-yl)ethyl ethylcarbamate
-
-
2-(4-(2H-tetrazol-5-yl) phenyl)-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(4-(2H-tetrazol-5-yl)phenyl)-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(4-(trifluoromethyl)benzyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.0005 mM with SK-N-SH cell, 0.030 mM with MCF-7 cell
2-(4-bromophenyl)-5-nitro[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
2-(4-dimethylaminoaniline)-isothiazol-3(2H)-one
-
-
2-(4-fluorophenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.010 mM with SK-N-SH cell, 0.037 mM with MCF-7 cell
2-(4-fluorophenyl)[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
PU139
2-(4-methylphenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.006 mM with SK-N-SH cell
2-(4-morpholinoaniline)-isothiazol-3(2H)-one
-
-
2-(4-pyridyl)-isothiazol-3(2H)-one
-
-
2-(4-[2-[3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)-1H-isoindole-1,3(2H)-dione
-
-
2-(4-[2-[5-(3,4-dimethoxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)-1H-isoindole-1,3(2H)-dione
-
-
2-(4-[2-[5-(furan-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)-1H-isoindole-1,3(2H)-dione
-
-
2-(6,7-dihydroxynaphthyl) beta-D-xylopyranoside
-
less than 50% residual activity at 0.1 mM
2-(6,7-dimethoxynaphthyl) beta-D-xylopyranoside
-
about 80% residual activity at 0.1 mM
2-(6-fluoro-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-(4-phenyl-1,3-thiazol-2-yl)acetamide
-
-
2-(6-hydroxy-7-methoxy-naphthyl) beta-D-xylopyranoside
-
less than 50% residual activity at 0.1 mM
2-(7-hydroxy-6-methoxy-naphthyl) beta-D-xylopyranoside
-
about 55% residual activity at 0.1 mM
2-(dimethylamino)-6-pentadecylpyrimidin-4(3H)-one
-
-
2-(dimethylamino)-6-tetradecylpyrimidin-4(3H)-one
-
-
2-(dimethylamino)-6-tridecylpyrimidin-4(3H)-one
-
-
2-(heptylsulfanyl)-1-(2-hydroxyphenyl)ethan-1-one
-
2-(hexylsulfanyl)-1-(2-hydroxyphenyl)ethan-1-one
-
-
2-(methylsulfanyl)-6-tridecylpyrimidin-4(3H)-one
-
-
2-(phenyl)-isothiazolo[5,4-b]pyridin-3(2H)-one
-
-
2-(S-coenzyme A)acetaldehyde
-
-
2-(S-coenzyme A)acetic acid
-
-
2-(S-coenzyme A)acetic acid thiophenyl ester
-
-
2-butyl-6-hydroxybenzoic acid
2-chloro-4-[5-[(E)-[3-[2-(4-methylanilino)-2-oxoethyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
-
C375
2-chloro-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
2-cyano-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
2-decyl-4-hydroxyquinoline-3-carboxylic acid
-
-
2-decyl-6-hydroxybenzoic acid
88% inhibition at 0.05 mM
2-dodecylmalonate
-
compound induces hyperacetylation of specific lysine residues of histone H3, in particular residues K9 and K18, and raises the level of pan-acetylated H4. Compound inhibits the acetylation of all the other H3 and H4 lysines, with the exception of residue K8Ac of histone H4
2-ethylisothiazol-3(2H)-one
-
2-fluoro-3-hydroxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-3-methyl-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-4-methyl-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-5-hydroxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-5-methoxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-5-methyl-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-6-methoxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(2-fluoro-5-methyl-3-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(2-fluoro-5-methyl-3-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(2-phenylisonicotinoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(4-fluoro-1H-pyrazol-1-yl)-5-methylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(4-fluoro-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(thiophen-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(thiophen-3-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-3-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-4-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-5-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-5-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(5-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)-3-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
competes with Ac-CoA by binding to the Ac-CoA binding site
2-fluoro-N'-(3-iodobenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-isobutoxybenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-isopropoxybenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-isopropylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(pyrimidin-2-yl)benzoyl)-benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(5-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-propoxybenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-propylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(4-fluoro-5-methyl-[1,1'-biphenyl]-3-carbonyl)benzenesulfonohydrazide
-
2-fluoro-N'-(5-fluoro-[1,1'-biphenyl]-3-carbonyl)-3-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(5-fluoro-[1,1'-biphenyl]-3-carbonyl)-4-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(5-fluoro-[1,1'-biphenyl]-3-carbonyl)-4-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(5-phenylnicotinoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(6-phenylpicolinoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(naphthalene-2-sulfonyl)benzohydrazide
2-fluoro-N'-(phenylsulfonyl)benzohydrazide
-
2-fluoro-N'-[(3-fluorophenyl)sulfonyl]benzohydrazide
-
2-fluoro-N'-[[3-(trifluoromethyl)phenyl]sulfonyl]benzohydrazide
-
2-hydroxy-5-nonylbenzoic acid
-
-
2-hydroxy-5-pentadecylbenzoic acid
85% inhibition at 0.05 mM
2-hydroxy-5-pentylbenzoic acid
-
2-hydroxy-5-tetradecylbenzoic acid
-
-
2-hydroxy-6-(11-hydroxyundecyl)benzoic acid
2-hydroxy-6-(5-hydroxypentyl)benzoic acid
-
2-hydroxy-6-nonylbenzoic acid
-
-
2-hydroxy-6-pentadecylbenzoic acid
2-hydroxy-6-tetradecylbenzoic acid
-
-
2-hydroxy-6-[(8E,11E)-pentadeca-8,11,14-trienyl]benzoic acid
-
2-hydroxy-6-[(E)-pentadec-8-enyl]benzoic acid
-
2-hydroxy-6-[(Z)-2-[4-(pentyloxy)phenyl]ethenyl]benzoic acid
-
-
2-hydroxy-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
2-pentylisothiazol-3(2H)-one
-
2-phenyl-5-(trityloxymethyl)isothiazol-3(2H)-one
-
-
2-phenylisothiazol-3(2H)-one
-
-
2-sulfanylidene-6-tridecyl-2,3-dihydropyrimidin-4(1H)-one
-
-
2-tert-butyl-5-(dodecylthio)isothiazol-3(2H)-one-1-oxide
-
-
2-tert-butyl-5-chloroisothiazol-3(2H)-one 1-oxide
-
-
2-tridecylmalonate
-
inhibition of the acetylation of histone H3 residuesK9/K18, being practically inactive in all the other assays
2-undecylmalonate
-
compound exhibits a significant inhibition of the acetylation of almost any lysine residue explored, with the sole exception of residue K8 of H4. Compound reduces the level of K5Ac of H4 and, more markedly, K16Ac of H4
2-[(1E)-1-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]ethyl]pyridine
-
2-[(1Z)-1-[(3E)-3-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]cyclopentylidene]ethyl]pyridine
-
-
2-[(3,4-dichlorophenyl)methyl]-1H-1l4-[1,2]thiazolo[5,4-b]pyridine-1,3(2H)-dione
-
-
2-[(3,4-dichlorophenyl)methyl]-1H-1l6-[1,2]thiazolo[5,4-b]pyridine-1,1,3(2H)-trione
-
-
2-[(4-bromophenyl)methyl]-5-methyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
NSC694614
2-[(4-methoxyphenyl)methyl]-5-nitro[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
NSC694622
2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acid
2-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-1,2-benzothiazol-3(2H)-one
-
-
2-[[4-(trifluoromethyl)phenyl]methyl][1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
PU141
3'-chloro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-cyano-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-fluoro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-methoxy-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate
ZINC65731330
3,3'-[(2-oxocyclohexane-1,3-diylidene)di(E)methanylylidene]dibenzonitrile
-
-
3-(2-(2-fluorobenzoyl)hydrazinylsulfono)benzamide
-
3-(Z)-(benzylsulfanyl)propenoic acid
-
-
3-(Z)-(benzylsulfinyl)-2-N-(4-dimethylaminoanilino)-propenamide
-
-
3-(Z)-(benzylsulfinyl)-2-N-(4-morpholinoanilino)-propenamide
-
-
3-(Z)-(benzylsulfinyl)-N-(2-pyridyl)propenamide
-
-
3-(Z)-(benzylsulfinyl)-N-(3-pyridyl)propenamide
-
-
3-(Z)-(benzylsulfinyl)-N-(4-pyridyl)propenamide
-
-
3-amino-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-bromo-N'-(3-ethoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
3-chloro-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-chloro-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
3-cyano-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-fluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(1H-pyrazol-1-yl)benzohydrazide
-
3-fluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(furan-2-yl)benzohydrazide
-
3-fluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(pyrimidin-2-yl)benzohydrazide
-
3-fluoro-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-methyl-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
3-pentadecylidenepentane-2,4-dione
-
inhibition of the acetylation of histone H3 residuesK9/K14, being practically inactive in all the other assays
3-quinolinecarboxylic acid ethyl ester
3-Z-benzylsulfanyl-4-trityloxy-but-2-enoic acid phenylamide
-
-
3-Z-benzylsulfinyl-4-trityloxy-but-2-enoic acid phenylamide
-
-
3-[(1E)-1-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]ethyl]-2H-1-benzopyran-2-one
-
3-[(1Z)-1-[(3E)-3-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]cyclopentylidene]ethyl]-2H-1-benzopyran-2-one
-
-
3-[(E)-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]methyl]-2,3-dihydro-1H-indole
-
3-[(Z)-[(3E)-3-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]cyclopentylidene]methyl]-1H-indole
-
-
3-[2-(pentadecanoylamino)benzamido]benzoic acid
-
-
3-[2-(tridecanoylamino)benzamido]benzoic acid
-
-
3-[2-[(2E)-2-(3-methylcyclopentylidene)hydrazinyl]-1,3-thiazol-4-yl]-2H-1-benzopyran-2-one
-
-
3-[2-[(2Z)-2-(3-methylcyclopentylidene)hydrazinyl]-1,3-thiazol-4-yl]-2H-1-benzopyran-2-one
-
3-[2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazol-4-yl]-2H-1-benzopyran-2-one
-
4'-chloro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4'-cyano-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4'-fluoro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4'-methoxy-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4,4'-(2-hydroxycyclohexane-1,3-diylidene)bis(methanylylidene)-bis(2-bromophenol)
12.5% residual activity at 0.1 mM
4,5-dichloro-2-ethylisothiazol-3(2H)-one
-
-
4,5-dichloro-2-ethylisothiazol-3(2H)-one-1-oxide
-
-
4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2-(4- (methylsulfonyl) phenyl)-2,4-dihydro-3H-pyrazol-3-one
-
4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2-(4-(methylsulfonyl)phenyl)-2,4-dihydro-3H-pyrazol-3-one
-
4-(3-cyclopropyl-4-((5-(4,5-dimethyl-2-(trifluoromethyl)phenyl)thiophen- 2-yl)methylene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-cyclopropyl-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-methyl-4-((5-(2-nitrophenyl)furan-2-yl)methylene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-methyl-5-oxo-4-((5-(2-(trifluoromethoxy)phenyl)furan-2-yl)methylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-methyl-5-oxo-4-((5-(3-oxo-2,3-dihydro-1H-inden-4-yl)furan-2-yl)methylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-oxo-1,2-benzothiazol-2(3H)-yl)butanoic acid
-
-
4-(4-((2-(4,5-dimethyl-2-nitrophenyl)thiazol-5-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(2-(difluoromethyl)phenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(2-(dimethylphosphoryl)phenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-1H-pyrrol-2-yl)methylene)-3-methyl-5-oxo-4, 5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-2,5-dioxoimidazolidin-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-ethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
C646, selective inhibitor
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzonitrile
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)thiophen-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-(1-(5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)ethylidene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-(2-((4,5-dimethyl-2-nitrophenyl)amino)-2-oxoethyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-(3-((4,5-dimethyl-2-nitrophenyl)amino)-3-oxopropyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-bromophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
4-(4-chlorophenyl)-2-[(2E)-2-(3-cyclooctylcyclopentylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(3-methylcyclopentylidene)hydrazinyl]-1,3-thiazole
-
CPTH6
4-(4-chlorophenyl)-2-[(2E)-2-[(3Z)-3-(1-cyclohexylethylidene)cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-[(3Z)-3-(4,4-dimethylcyclohex-2-en-1-ylidene)cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-[(3Z)-3-[1-(1,3-thiazol-2-yl)ethylidene]cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-[1-(1,3-thiazol-2-yl)ethylidene]hydrazinyl]-1,3-thiazole
-
4-(4-chlorophenyl)-2-[(2E)-2-[3-(propan-2-ylidene)cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
-
4-(4-nitrophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
-
-
4-(5-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-2,4- dioxothiazolidin-3-yl)benzoic acid
-
4-(5-(4,5-dimethyl-2-nitrobenzoyl)-1H-indazol-1-yl)benzoic acid
-
4-(5-(4,5-dimethyl-2-nitrobenzoyl)-1H-indol-1-yl)benzoic acid
-
4-(5-(4,5-dimethyl-2-nitrobenzyl)-1H-indazol-1-yl)benzoic acid
-
4-(aminoacetyl)-N-benzyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-([(2E)-2-cyano-3-[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]prop-2-enoyl]amino)benzoic acid
-
4-([4-[3-(methoxycarbonyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-4-yl]phenoxy]methyl)benzoic acid
-
-
4-acetyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-2-methyl-N-(morpholin-4-yl)-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
4-acetyl-2-methyl-N-phenyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-2-methyl-N-propyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N,N-dibenzyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-benzyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-cyclohexyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-[(3-bromophenyl)methyl]-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-amino-1-naphthol
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 4A1N
4-amino-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
4-azidomethyl-2-phenyl-isothiazol-3(2H)-one
-
-
4-bromomethyl-2-phenylisothiazol-3(2H)-one
-
-
4-butoxy-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
4-chloro-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
4-cyano-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
4-hydroxy-2-methylquinoline-3-carboxylic acid
-
-
4-hydroxy-2-pentadecylquinoline-3-carboxylic acid
-
-
4-hydroxy-2-pentylquinoline-3-carboxylate
-
effects in vivo, overview, in vitro clear reduction of the acetylation extents of both histone H3 and alpha-tubulin at 0.1 mM
4-hydroxy-2-pentylquinoline-3-carboxylic acid
4-hydroxy-3-[(E)-[[2-(3-iodophenyl)-1,3-benzoxazol-5-yl]imino]methyl]benzoic acid
-
C146
4-hydroxy-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
4-methoxymethyl-2-phenyl-isothiazol-3(2H)-one
-
-
4-methyl-2-phenylisothiazol-3(2H)-one
-
-
4-methyl-5-methoxy-2-phenyl-isothiazol-3(2H)-one
-
-
4-trityloxy-but-2-ynoic acid phenylamide
-
-
4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)benzamide
i.e. C646-yne, docking study and protein interaction analysis, formation of a stable C646-cysteine adducts. The major targets of C646-yne reactivity are abundant cellular proteins containing reactive cysteine residues
4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
i.e. C646, inhibits the lysine acetyltransferases (KATs) p300 and CBP and represents a very potent and selective small molecule KAT inhibitor, docking study and protein interaction analysis. The pyrazolone-furan of C646 is an electrophilic chemotype capable of irreversible protein reactivity
4-[2-(pentadecanoylamino)benzamido]benzoic acid
-
-
4-[2-(tridecanoylamino)benzamido]benzoic acid
-
-
4-[4-(3,4-dicarboxybenzamido)phenoxy]benzene-1,2-dicarboxylic acid
ZINC03143991
4-[4-(3,4-dimethylbenzamido)phenoxy]benzene-1,2-dicarboxylic acid
-
4-[4-(3-methylbenzamido)phenoxy]benzene-1,2-dicarboxylic acid
ZINC09694266
4-[[(4-methoxybenzene-1-sulfonyl)oxy]imino]-2,6-dimethylcyclohexa-2,5-dien-1-one
-
L002
4-[[2,6-dibromo-4-(3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)phenoxy]methyl]benzoic acid
-
DC-G16-11
4-[[2,6-dichloro-4-(1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)phenoxy]methyl]benzoic acid
-
-
4-[[2-bromo-4-(3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)phenoxy]methyl]benzoic acid
-
-
4-[[4-(1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)-2-methoxyphenoxy]methyl]benzoic acid
-
-
4-[[4-(3-cyano-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-4-yl)phenoxy]methyl]benzoic acid
-
-
4-[[4-(8-oxo-7,8,9,10,11,12-hexahydrobenzo[c]acridin-7-yl)phenoxy]methyl]benzoic acid
-
-
5,5'-disulfanediylbis(1,2-thiazole)
-
NU9056
5,5'-[(5-carboxy-2-oxocyclohexane-1,3-diylidene)bis(methanylylidene)]bis(2-hydroxybenzoic acid)
70.1% residual activity at 0.1 mM
5-acetoxymethyl-2-phenylisothiazol-3(2H)-one
-
-
5-azidomethyl-2-phenylisothiazol-3(2H)-one
-
-
5-bromo-2-(dimethylamino)-6-tetradecylpyrimidin-4(3H)-one
-
-
5-bromo-2-(dimethylamino)-6-tridecylpyrimidin-4(3H)-one
-
-
5-bromo-N'-(3-ethoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
5-butyl-2-hydroxybenzoic acid
-
-
5-chloro-2-(3-chloro-4-fluorophenyl)isothiazol-3(2H)-one
-
5-chloro-2-(4-nitrophenyl)-1,2-thiazol-3(2H)-one
-
CCT077791
5-chloro-2-ethyl-4-methyl-1H-1l4,2-thiazole-1,3(2H)-dione
-
-
5-chloro-2-ethyl-4-methylisothiazol-3(2H)-one
-
-
5-chloro-2-ethyl-4-methylisothiazol-3(2H)-one-1-oxide
-
-
5-chloro-2-ethylisothiazol-3(2H)-one
5-chloro-2-ethylisothiazol-3(2H)-one-1-oxide
-
-
5-chloro-2-pentylisothiazol-3(2H)-one
-
5-chloro-4-methyl-2-phenylisothiazol-3(2H)-one
-
-
5-chloro-6-[([1-[(2R)-2-hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]piperidin-4-yl]amino)methyl]-1,3-benzoxazol-2(3H)-one
-
5-decyl-2-hydroxybenzoic acid
95% inhibition at 0.05 mM
5-hydroxy-2,3-dimethylnaphthalene-1,4-dione
-
PTK1
5-hydroxy-2-methylnaphthalene-1,4-dione
-
RTK1
5-hydroxymethyl-2-phenylisothiazol-3(2H)-one
-
-
5-methyl-2-phenylisothiazol-3(2H)-one
-
-
5-phenylureidomethyl-2-phenylisothiazol-3(2H)-one
-
-
6-(4-chlorophenyl)-2-(2-(3-methylcyclopentylidene)hydrazinyl)pyrimidin-4(3H)-one
-
6-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)pyrimidin-4(3H)-one
-
6-(4-chlorophenyl)-2-[(2E)-2-(3-methylcyclopentylidene)hydrazinyl]pyrimidin-4(3H)-one
-
-
6-dodecyl-2-(methylsulfanyl)pyrimidin-4(3H)-one
-
-
6-dodecyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one
-
-
6-[(4S)-5-(ethoxycarbonyl)-6-methyl-2-oxo-4-phenyl-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
ZINC14246093
6-[(4S)-5-(ethoxycarbonyl)-6-methyl-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
ZINC40152345
6-[(4S)-5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
-
6-[(4S)-5-[(benzyloxy)carbonyl]-4-([1,1'-biphenyl]-4-yl)-6-methyl-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
ZINC08829517
8-benzyl-10,11-dimethoxy-5,6,7,9,14,14a-hexahydro-2H-[1,3]dioxolo[4,5-h]isoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
8-benzyl-11,12-dimethoxy-5,6,7,9,14,14a-hexahydro-2H-[1,3]dioxolo[4,5-h]isoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
8-benzyl-2,3,10,11-tetramethoxy-5,6,7,9-tetrahydroisoquinolino[3,2-a][2]benzazepin-8-ium chloride
-
-
8-benzyl-2,3,11,12-tetramethoxy-5,6,7,9-tetrahydroisoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
9-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione
-
-
9-[4-(benzyloxy)-3-bromophenyl]-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione
-
-
Ac-ARTK(me)QTARK(me)3STGGK(CoA)APRKQL
-
-
Ac-ARTK(me)QTARKSTGGK(Br)APRKQL
-
-
Ac-ARTK(me)QTARKSTGGK(CoA)APRKQL
-
-
Ac-ARTKQTARK(me)3STGGK(Sme)APRKQL
-
-
Ac-ARTKQTARKSTGGK(Br)APRKQL
-
-
Ac-ARTKQTARKSTGGK(CoA)APRKQL
-
-
Ac-L-Lys(CoA)-NH2
bisubstrate inhibitor
acetylated histone H3 peptide
-
allspice hot water extract
-
leads to a potent anti-HAT activity since the allspice hot water extract possesses a strong inhibitory effect on p300 and CBP (40% at 0.1 ng/ml). Chromatin immunoprecipitation indicates that the acetylation of histone H3 in the PSA and B2M promoter regions was also repressed
-
B-homo berberine
-
10,11-dimethoxy-6,7-dihydro-2H,5H-[1,3]dioxolo[4,5-h]isoquinolino[3,2-a][2]benzazepin-8-ium methanesulfonate
B-homo palmatine
-
2,3,10,11-tetramethoxy-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium methanesulfonate
benzyl [2-(5-chloro-3-oxoisothiazol-2(3H)-yl)ethyl]carbamate
-
BF1
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
bisubstrate analogue histone H3-peptide-coenzyme A
-
bisubstrate analogue methyl-histone H3-peptide-coenzyme A
-
peptide consisting of 20 and 7 amino acid residues
-
CCT004463
-
in vivo cell proliferation inhibition
CCT004464
-
in vivo cell proliferation inhibition
CCT004465
-
in vivo cell proliferation inhibition
CCT004466
-
in vivo cell proliferation inhibition
CCT004467
-
in vivo cell proliferation inhibition
CCT077791
-
IC50: 0.0022-0.0073 mM, in vivo cell proliferation inhibition, reduces acetylation of histones H3 and H4 and alpha-tubulin in cancer cell lines
CCT077792
-
IC50: 0.0027-0.015 mM, in vivo cell proliferation inhibition
CCT077796
-
IC50: 0.0187-0.0202 mM, in vivo cell proliferation inhibition
CCT079769
-
IC50: 0.0547 mM, in vivo cell proliferation inhibition
CPTH6
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 27% inhibition at 0.1 mM; 40% inhibition at 0.8 mM; 40% inhibition at 0.8 mM
CtpB
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
-
CTX-0124143
i.e. N'-(2-fluorobenzoyl)naphthalene-2-sulfonohydrazide
Cu2+
-
5 mM, enzyme form B
DELTA12-prostaglandin J2
-
-
diethyl (1-aminotetradecyl)propanedioate
-
-
diethyl (1-chlorotetradecyl)propanedioate
-
-
diethyl (1-hydroxytetradecyl)propanedioate
-
-
diethyl (pentadecan-2-yl)propanedioate
-
-
diethyl 2-tetradecylidenemalonate
-
compound exhibits a significant inhibition of the acetylation of almost any lysine residue explored, with the sole exception of residue K8 of H4. Compound reduces the level of K5Ac of H4 and, more markedly, K16Ac of H4
diethyl benzylidenepropanedioate
-
-
diethyl decylidenepropanedioate
-
-
diethyl dodecylidenepropanedioate
-
-
diethyl dodecylpropanedioate
-
-
diethyl pentadecylidenepropanedioate
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 i.e. SPV106, a long-chain alkylidenemalonate (LoCAM), 74% inhibition at 0.05 mM
diethyl tetradecylidenepropanedioate
-
-
diethyl tetradecylpropanedioate
-
-
diethyl tridecylidenepropanedioate
-
-
diethyl tridecylpropanedioate
-
-
diethyl undecylidenepropanedioate
-
-
diethyl [(dodecylamino)methylidene]propanedioate
-
-
diethyl [(naphthalen-1-yl)methylidene]propanedioate
-
-
diethyl [(naphthalen-2-yl)methylidene]propanedioate
-
-
dimethyl sulfoxide
-
irreversible at 2% v/v
dithiothreitol
-
10 mM: stimulation, 100 mM: inhibition
embelin
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
EML425
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
epigallocatechin-3-gallate
ethanol
-
irreversible at 2% v/v
ethyl (2E)-2-acetylheptadec-2-enoate
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
ethyl (2E)-2-acetylhexadec-2-enoate
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
ethyl (3E,5E)-3,5-bis[(3-bromo-4-hydroxyphenyl)methylidene]-4-oxocyclohexane-1-carboxylate
-
-
ethyl 2-decyl-4-hydroxyquinoline-3-carboxylate
-
-
ethyl 2-methyl-6-([5-[(prop-2-yn-1-yl)amino]pentyl]oxy)quinoline-3-carboxylate
ethyl 2-methylquinoline-3-carboxylate
ethyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoate
-
ethyl 4-hydroxy-2-methylquinoline-3-carboxylate
-
-
ethyl 4-hydroxy-2-pentadecylquinoline-3-carboxylate
-
-
ethyl 4-hydroxy-2-pentylquinoline-3-carboxylate
-
-
ethyl 4-oxo-2-sulfanylidene-6-tetradecyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate
-
-
ethyl quinoline-3-carboxylate
-
MC1752
gamma-butyrolactone
-
MB-3
geminin
-
a Cdt1 repressor, inhibits HBO1 acetylase activity in a a Cdt1-dependent manner in the context of a Cdt1-HBO1 complex, and it associates with origins and inhibits H4 acetylation and licensing in vivo, but geminin does not block the interaction of Cdt1 with HBO1 in vitro or Cdt1-dependent recruitment of HBO1 to replication origins in vivo
-
H3-CoA-20-Tat
-
IC50: 0.012 mM, recombinant enzyme
-
HC toxin
cyclic tetrapeptide, decreases enzyme form B expression
heparan sulfate proteoglycans
-
heparan sulfate proteoglycans isolated from corneal and pulmonary fibroblasts inhibit HAT activity with similar effectiveness as heparin
-
heparin
-
ability of heparin to inhibit HAT is dependent upon its size and structure: small heparin-derived oligosaccharides (above 8 sugars) and N-desulfated or O-desulfated heparin show reduced inhibitory activity. Heparin is shown to bind to pCAF. Enzyme assays indicate that heparin shows the characteristics of a competitive-like inhibitor causing a 50fold increase in the Km of pCAF for histone H4
histone H3-peptide mutant K14A
-
dead-end inhibitor analogue, mutant histone H3 -peptide consisting of amino acid residues 3-20 K14A
-
Isopropanol
-
irreversible at 2% v/v
L002
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 i.e. NSC764414
LTK-14
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
Lys-CoA-Tat
-
IC50: 250 nM, recombinant enzyme, complete inhibition of acetylation of the promyelotic leukemia zinc finger gene
MC1626
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
MC1752
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
MC1823
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
methyl 2-(5-chloro-3-oxoisothiazol-2(3H)-yl)ethanoate
-
methyl 3-(3-oxoisothiazol-2(3H)-yl)propanoate
-
methyl 3-(4,5-dichloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(4,5-dichloro-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-1,3-dioxo-1,3-dihydro-2H-1l4,2-thiazol-2-yl)propanoate
-
-
methyl 3-(5-chloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
methyl 3-(5-chloro-3-oxo-1,2-thiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoic acid
-
methyl 3-(5-chloro-4-methyl-1,3-dioxo-1,3-dihydro-2H-1l4,2-thiazol-2-yl)propanoate
-
-
methyl 3-(5-chloro-4-methyl-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-4-methyl-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-[(5-chloro-1,2-thiazol-3-yl)amino]propanoate
-
-
methyl 3-[(5-chloroisothiazol-3-yl)amino]propanoate
-
methyl 3-[4-chloro-5-(dodecylthio)-1-oxido-3-oxoisothiazol-2(3H)-yl]propanoate
-
-
methyl 3-[4-[[(benzyloxy)carbonyl]amino]-5-chloro-3-oxo-1,2-thiazol-2(3H)-yl]propanoate
-
-
methyl 3-[4-{[(benzyloxy)carbonyl]amino}-5-chloro-3-oxoisothiazol-2(3H)-yl]propanoate
-
methyl 3-[5-(dodecylthio)-1-oxido-3-oxoisothiazol-2(3H)-yl] propanoate
-
-
methyl 4-(3-oxoisothiazol-2(3H)-yl)butanoate
-
methyl 4-(5-chloro-3-oxoisothiazol-2(3H)-yl)butanoate
-
methyl 5-(5-chloro-3-oxoisothiazol-2(3H)-yl)pentanoate
-
methyl 6-(5-chloro-3-oxoisothiazol-2(3H)-yl)hexanoate
-
montelukast
-
decreases HAT activity by attenuating the activating effect of TNF-alpha
N'-( 2-fluoro-[1,1'- biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(2,3-difluorobenzoyl)benzenesulfonohydrazide
-
N'-(2,3-difluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-fluoro-5-propoxybenzohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-fluoro-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-methoxy-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-methyl-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(2-dluorobenzoyl)-4-methylbenzenesulfonohydrazide
-
N'-(2-fluoro-3-(trifluoromethyl)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-(trifluoromethyl)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-3-methoxybenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-((2-methylallyl)oxy)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-((2-methylallyl)oxy)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(2H-1,2,3-triazol-2-yl)benzoyl)-naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(5-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(4-fluoro-1H-pyrazol-1-yl)-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(furan-2-yl)-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-isopropoxy-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-isopropoxybenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-5-propoxybenzoyl)benzenesulfonohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(furan-2-yl)-5-methoxybenzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(furan-2-yl)-5-methylbenzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(naphthalen-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(pyrimidin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(pyrimidin-4-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(trifluoromethoxy)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-methoxy-5-(pyridin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-methyl-5-(pyridin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-methyl-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)benzohydrazide
-
N'-(2-fluorobenzoyl)-2-methoxybenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-2-methylbenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-3-methoxybenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-3-methylbenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-4-methoxybenzenesulfonohydrazide
-
N'-(2-methoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-phenylisonicotinoyl)benzenesulfonohydrazide
-
N'-(3-(1,2,4-oxadiazol-3-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(1,3,4-oxadiazol-2-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(1H-pyrazol-1-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
N'-(3-(3,5-dimethyl-1H-pyrazol-1-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(4-fluoro-1H-pyrazol-1-yl)-5-methylbenzoyl)benzenesulfonohydrazide
-
N'-(3-(allyloxy)-5-fluorobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(allyloxy)-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(allyloxy)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopentyloxy)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopentyloxy)benzoyl)benzenesulfonohydrazide
-
N'-(3-(cyclopropylmethoxy)-5-fluorobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopropylmethoxy)-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopropylmethoxy)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(ethoxymethyl)-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(furan-2-yl)-5-methoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-(furan-2-yl)-5-methylbenzoyl)benzenesulfonohydrazide
-
N'-(3-(piperazin-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyridin-3-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyrimidin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyrimidin-5-yl)benzoyl)benzenesulfonohydrazide
N'-(3-(thiazol-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(thiazol-4-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(thiophen-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(thiophen-3-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(trifluoromethoxy)benzoyl)benzenesulfonohydrazide
-
N'-(3-(trifluoromethoxy)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-(trifluoromethyl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(trifluoromethyl)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-acetylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-aminobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-bromobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-butoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-butoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-chloro-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(3-chloro-2-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-chloro-5-(furan-2-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-chloro-5-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-chloro-5-(thiophen-2-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-cyanobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-cyclopropoxy-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-fluorobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,3-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,4-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,5-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,6-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluoro-3-methylbenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluoro-4-methylbenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluoro-5-methylbenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)-2-fluoro-5-methoxybenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)-2-fluoro-6-methoxybenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-ethyl-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(3-ethyl-2-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-ethylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethylbenzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-propoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-isobutoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-isopropoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-isopropylbenzoyl)benzenesulfonohydrazide
-
N'-(3-isopropylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-methoxy-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-methoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-methoxylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(3-phenoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-propoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-propoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-propylbenzoyl)benzenesulfonohydrazide
-
N'-(4-(trifluoromethoxy)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-cyanobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-fluoro-5-methyl-[1,1'-biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(4-fluoro-[1,1'-biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(4-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-methoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(5-(allyloxy)-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(5-(allyloxy)-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(5-(allyloxy)-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(5-(cyclopropylmethoxy)-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(5-(cyclopropylmethoxy)-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(5-(ethoxymethyl)-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(5-(ethoxymethyl)-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(5-chloro-4-fluoro-[1,1'-biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(5-ethoxy-2-fluoro-3-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(5-ethoxy-2-fluoro-3-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(5-ethoxy-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(5-phenylnicotinoyl)benzenesulfonohydrazide
-
N'-(6-phenylpicolinoyl)benzenesulfonohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-3-methyl-5-(pyridin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-3-methyl-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-3-methyl-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-5-(pyridazin-4-yl)benzohydrazide
-
WM-2474
N'-(benzenesulfonyl)-2-fluoro-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-5-(pyrimidin-4-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-5-[(prop-2-yn-1-yl)oxy]benzohydrazide
-
N'-(benzenesulfonyl)-3-fluoro-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-3-fluorobenzohydrazide
-
N'-(benzenesulfonyl)-3-methoxy-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-3-methoxybenzohydrazide
-
N'-(benzenesulfonyl)-3-methyl-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-4-fluoro-5-methyl[1,1'-biphenyl]-3-carbohydrazide
N'-(benzenesulfonyl)-5-chloro-4-fluoro[1,1'-biphenyl]-3-carbohydrazide
-
N'-(ethoxy-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(ethoxy-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
N'-(naphthalene-2-sulfonyl)benzohydrazide
-
N'-([1,1'-biphenyl]-3-carbonyl)-2-fluorobenzenesulfonohydrazide
-
N'-([1,1'-biphenyl]-3-carbonyl)benzenesulfonohydrazide
-
N'-([1,1'-biphenyl]-3-carbonyl)naphthalene-2-sulfonohydrazide
-
N'-benzoylbenzenesulfonohydrazide
-
N'-[(3-bromophenyl)sulfonyl]-2-fluorobenzohydrazide
-
N'-[(3-ethylphenyl)sulfonyl]-2-fluorobenzohydrazide
-
N'-[(4-bromophenyl)sulfonyl]-2-fluorobenzohydrazide
-
N-(2-fluoro-3-methyl-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
N-(2-fluoro-3-methyl-5-propoxybenzoyl)-benzenesulfonohydrazide
-
N-(2-fluoro-3-methyl-5-propoxybenzoyl)benzenesulfonohydrazide
-
N-(2-fluoro-4-[[(1-hydroxy-3-methylbenzo[f]quinazolin-9-yl)methyl]amino]benzoyl)-L-glutamic acid
-
N-(3-aminopropyl)acetamido-CoA
-
-
N-(3-benzamidobutyl)acetamido-CoA
-
-
N-(3-benzamidopentyl)acetamido-CoA
-
-
N-(3-benzamidopropyl)acetamido-CoA
-
-
N-(3-[[(2,2-dimethylpropanoyl)oxy]amino]propyl)acetamido-CoA
-
-
N-(4-acetyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonyl)benzamide
-
-
N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide
-
-
N-(4-chlorophenyl)-2-(4,6-dimethyl-3-oxo[1,2]thiazolo[5,4-b]pyridin-2(3H)-yl)acetamide
-
-
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-decyl-6-ethoxybenzamide
-
inhibits human p300 recombinant enzyme similar to anacardic acid
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-ethoxy-6-octylbenzamide
-
inhibits human p300 recombinant enzyme similar to anacardic acid, moreover this inhibitor induces significant apoptosis at 0.05 nM in U937 leukemia cells
N-(4-[[(1-hydroxy-3-methylbenzo[f]quinazolin-9-yl)methyl]amino]cyclohexane-1-carbonyl)-L-glutamic acid
-
N-(4-[[(2,2-dimethylpropanoyl)oxy]amino]butyl)acetamido-CoA
-
-
N-(4-[[(2-amino-4-hydroxyquinazolin-6-yl)methyl](formyl)amino]benzoyl)-L-glutamic acid
-
N-(4-[[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](cyanomethyl)amino]benzoyl)-L-glutamic acid
ZINC29250560
N-(4-[[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]benzoyl)-L-glutamic acid
N-(4-[[(2-amino-7-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]benzoyl)-L-glutamic acid
-
N-(4-[[4-(2-amino-6-oxo-1,6-dihydropyrimidin-5-yl)benzene-1-sulfonyl]amino]benzoyl)-L-glutamic acid
-
N-(5-[[(2,2-dimethylpropanoyl)oxy]amino]pentyl)acetamido-CoA
-
-
N-benzyl-2,4-dimethyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-2-methyl-4-(phenylacetyl)-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-4-(chloroacetyl)-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-4-(cyclohexanecarbonyl)-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-4-(cyclopropanecarbonyl)-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzylacetamido-CoA
-
-
N-[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]-N-[(4-fluorophenyl)methyl]-2-[(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-[1,3]oxazolidin]-3'-yl]acetamide
-
-
N-[(2-chloro-6-fluorophenyl)methyl]-2-(2,5-dioxo-4-phenyl-4-propylimidazolidin-1-yl)-N-methylacetamide
-
-
N-[(3S)-5-[[(1S)-3-(5-[[(5S)-5-(3-carbamimidamidopropyl)-3,6-dioxopiperazin-2-yl]methyl]-2-hydroxyphenoxy)-1-carboxypropyl]amino]-3-carboxy-3-hydroxy-5-oxopentanoyl]-L-aspartic acid
-
NK13650A
N-[(4-fluorophenyl)methyl]-2-[(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-[1,3]oxazolidin]-3'-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide
N-[2-(2,5-dimethoxybenzoyl)-3-methyl-1-benzofuran-6-yl]-3,5-dimethoxybenzamide
-
F2209-0381
N-[2-(S-Coenzyme A)acetyl]spermidine amide
-
strong
N-[4-([[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl]amino)benzoyl]-L-glutamic acid
ZINC34633488
N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-tetradecylbenzamide
-
-
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-ethoxy-6-heptylbenzamide
-
-
N-[4-[(2-methyl-4-oxo-3,4-dihydroquinazoline-6-sulfonyl)amino]benzoyl]-L-glutamic acid
-
N-[5-[(5-[[5-([4-[(5-[[5-([5-[(5-[[3-(dimethylamino)propyl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)amino]-4-oxobutyl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]-4-[(N-[[2-(2-[4-[(4Z)-4-[[5-(2,3-dimethyl-6-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]benzamido]ethoxy)ethoxy]acetyl]-beta-alanyl)amino]-1-methyl-1H-pyrrole-2-carboxamide
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
N6-Acetyllysine
-
competitive
NK13650A
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
NK13650B
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
peptide conjugate Boc-C5-CoA
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 peptide Boc-C5-CoA, the molecule exploits an additional electron-rich pocket (P2) about 10 A away from the lysine binding pocket (P1). Boc-C5-CoA that shows high affinity for, comprises a CoA moiety which binds to the P1 pocket, a 1,5-pentanediamine linker and a tert-butoxycarbonyl cap, which is accommodated by the P2 pocket. CoA is connected to the N1 of the linker through a carboxymethylene bridge, while the tert-butoxycarbonyl cap protects the N5
-
peptide conjugate H3-CoA-20
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 peptide H3-CoA-20 resembles the K14-containing sequence of histone H3, the main substrate of PCAF, R1 is A-P-R-K-Q-L-OH and R2 is G-G-T-S-L-R-A-T-Q-K-T-R-A-NHCH3
-
peptide conjugate H4-K16-CoA
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 peptide H4-K16-CoA, R1 is K-A-G-G-K-G-L-G-K-G-G-K-G-R-G-S-OCH3 and R2 is R-H-R-K-NH2; peptide H4-K16-CoA, R1 is K-A-G-G-K-G-L-G-K-G-G-K-G-R-G-S-OCH3 and R2 is R-H-R-K-NH2
-
phenylpyrazolocurcumin CTK7A
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
potassium phosphate
-
90 mM
PU139
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
S-(4-benzylpiperazin-1-yl)(1-oxo)ethyl-CoA
-
-
S-(piperazin-1-yl)(1-oxo)ethyl-CoA
-
-
S-(tert-butyl 4-acetylpiperazin-1-yl)(1-oxo)ethyl-CoA
-
-
Sea urchin sperm chromatin
-
-
-
siRNA
-
silencing of enzyme gene
-
sodium 4-[3,5-bis[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1H-pyrazol-1-yl]benzoate
-
CTK7A
Spd(N1)-CoA
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 obtained by linking the polyamine spermidine to CoA using a carboxymethylene bridge
spermidine
-
inhibits histone acetylation at high concentrations, enzyme forms A and B
tert-butyl-(3-(2-(naphthalen-2-ylsulfono)hydrazinecarbonyl)-phenyl)carbamate
-
tetradecylidenepropanedioic acid
-
EML264
TH1834
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 60% inhibition at 0.5 mM
tridecylidenepropanedioic acid
-
-
TTK21
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
WM-8014
highly potent inhibitor, competitive inhibition with respect to acetyl-CoA
[(3,7-dimethyloctyl)oxy]benzene
-
-
[5-(4-[[(2-phenylethyl)(4-[4-[(pyrrolidin-1-yl)methyl]phenoxy]butyl)amino]methyl]phenyl)-2H-tetrazol-2-yl]acetic acid
-
TH1834
[histone H4]-L-lysine12-CoA
bisubstrate inhibitor, i.e. Ac-SGRGKGGKGLGK(CoA)GGAKRHRK, competitive inhibition with respect to both acetyl-CoA and histone H4, highly specific inhibitor for histone acetyltransferase 1
-
[histone H4]-L-lysine16-CoA
-
[histone H4]-L-lysine5-CoA
bisubstrate inhibitor, i.e. Ac-SGRGK(CoA)GGKGLGKGGAKRHRK
-
[histone H4]-L-lysine8-CoA
bisubstrate inhibitor, i.e. Ac-SGRGKGGK(CoA)GLGKGGAKRHRK
-
(2E,6E)-2,6-bis[(3,5-dibromo-4-hydroxyphenyl)methylidene]cyclohexan-1-one
complete inhibition at 0.1 mM
(2E,6E)-2,6-bis[(3,5-dibromo-4-hydroxyphenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(4-hydroxyphenyl)methylidene]cyclohexan-1-one
28.6% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(4-hydroxyphenyl)methylidene]cyclohexan-1-one
-
-
(E)-4-(2-(5,6-dimethylbenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
96% inhibition at 0.1 mM
(E)-4-(2-(5,6-dimethylbenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
-
-
(E)-4-(2-(5-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
82% inhibition at 0.1 mM
(E)-4-(2-(5-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
-
-
(E)-4-(2-(5-chlorobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
89% inhibition at 0.1 mM
(E)-4-(2-(5-chlorobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
-
-
(E)-4-(2-(6-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
21% inhibition at 0.1 mM
(E)-4-(2-(6-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-2-chloro-N,N-diethylbenzenesulfonamide
12% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-2-chloro-N,N-diethylbenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-fluorobenzenesulfonamide
18% inhibition at 0.1 mM; 28% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-fluorobenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-methylbenzenesulfonamide
30% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-methylbenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
competitive inhibition, complete inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylbenzenesulfonamide
14% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylbenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methoxyphenyl)benzenesulfonamide
28% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methoxyphenyl)benzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methylbenzyl)benzenesulfonamide
33% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methylbenzyl)benzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-benzylbenzenesulfonamide
11% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-benzylbenzenesulfonamide
-
-
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-phenylbenzenesulfonamide
25% inhibition at 0.1 mM
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-phenylbenzenesulfonamide
-
-
(E)-N,N-diethyl-4-(2-(5-fluorobenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
84% inhibition at 0.1 mM
(E)-N,N-diethyl-4-(2-(5-fluorobenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
-
-
(E)-N,N-diethyl-4-(2-(5-methoxybenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
13% inhibition at 0.1 mM
(E)-N,N-diethyl-4-(2-(5-methoxybenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
-
-
(E)-N,N-diethyl-4-(2-(5-methylbenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
14% inhibition at 0.1 mM
(E)-N,N-diethyl-4-(2-(5-methylbenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
-
-
1-(4-(4-chlorophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
i.e. BF1, shows substrate selectivity for histone H3 acetylation and inhibitory activity in vitro on recombinant HATs Gcn5 and p300. Both global acetylation of histone H3 and specific acetylation at lysine 18 (H3AcK18) are lowered by BF1 treatment
1-(4-(4-chlorophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
i.e. BF1, shows substrate selectivity for histone H3 acetylation and inhibitory activity in vitro on recombinant HATs Gcn5 and p300. Both global acetylation of histone H3 and specific acetylation at lysine 18 (H3AcK18) are lowered by BF1 treatment
2,6-bis(3-bromo-4-hydroxybenzylidene)cyclohexanone
-
-
2,6-bis(3-bromo-4-hydroxybenzylidene)cyclohexanone
RC56, specific inhibitor, complete inhibition at 0.1 mM
2,6-bis(3-bromo-4-hydroxybenzylidene)cyclohexanone
-
RC56, cinnamoyl-III
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-butyl-6-hydroxybenzoic acid
-
2-butyl-6-hydroxybenzoic acid
-
-
2-fluoro-N'-(naphthalene-2-sulfonyl)benzohydrazide
-
CTx-0124143
2-fluoro-N'-(naphthalene-2-sulfonyl)benzohydrazide
i.e. CTX-0124143, a reversible Ac-CoA-competitive inhibitor of KAT6A
2-hydroxy-6-(11-hydroxyundecyl)benzoic acid
-
2-hydroxy-6-(11-hydroxyundecyl)benzoic acid
-
-
2-hydroxy-6-pentadecylbenzoic acid
i.e. anacardic acid, 97% inhibition at 0.05 mM
2-hydroxy-6-pentadecylbenzoic acid
-
2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acid
complete inhibition at 0.05 mM
2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acid
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
3-quinolinecarboxylic acid ethyl ester
-
effects in vivo, overview
3-quinolinecarboxylic acid ethyl ester
-
effects in vivo, inhibitory effect on the transcription is not fully GCN5-specific, overview
4-(4-bromophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
-
4-(4-bromophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
CPTH2
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
4-acetyl-2-methyl-N-(morpholin-4-yl)-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-2-methyl-N-(morpholin-4-yl)-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
4-hydroxy-2-pentylquinoline-3-carboxylic acid
-
-
4-hydroxy-2-pentylquinoline-3-carboxylic acid
-
MC1823
4-hydroxy-2-pentylquinoline-3-carboxylic acid
-
4-hydroxy-2-pentylquinoline-3-carboxylic acid
-
-
5-chloro-2-ethylisothiazol-3(2H)-one
-
5-chloro-2-ethylisothiazol-3(2H)-one
-
-
A-485
-
A-485
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
acetylated histone H3 peptide
-
acetylated at Lys14, product inhibition of PCAF protein, noncompetitive against both substrates
-
acetylated histone H3 peptide
-
noncompetitive versus acetyl-CoA and histone H3
-
anacardic acid
-
anacardic acid
-
anarcardic acid supresses TNF-induced HAT activity
anacardic acid
-
10 microM inhibit histidine-tagged recombinant p300 with purified human HeLa core histone as substrate by about 95%
anacardic acid
-
a p300HAT inhibitor
anacardic acid
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
anacardic acid
-
reversibly and noncompetitively inhibits HAT activity with a 50% inhibitory concentration of 0.03 nM. The parasiticidal effect of anacardic acid is at least partially associated with its inhibition of PfGCN5 HAT, resulting in the disturbance of the transcription program in the parasites
bisubstrate analogue histone H3-peptide-coenzyme A
-
potent inhibitor, competitive versus acetyl-CoA, non-competitive versus histone H3-peptide
-
bisubstrate analogue histone H3-peptide-coenzyme A
-
peptide consisting of 20 and 7 amino acid residues
-
bisubstrate analogue histone H3-peptide-coenzyme A
-
-
-
Brij-58
-
-
C646
-
C646
CBP/p300-specific histone acetyltransferase inhibitor, that inhibits proliferation of hepatocellular carcinoma cell lines in a dose-dependent manner; CBP/p300-specific histone acetyltransferase inhibitor, that inhibits proliferation of hepatocellular carcinoma cell lines in a dose-dependent manner
C646
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
Ca2+
-
-
Ca2+
-
Mg2+ or Ca2+ required at low concentration of 5 mM, inhibition at 10-20 mM
CoA
-
-
CoA
-
product inhibition of PCAF protein, competitive against acetyl-CoA
CoA
-
competitive versus acetyl-CoA, Gnc5 protein
CoA
CoA binds competitively with acetyl-CoA
CPTH2
-
CPTH2
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
curcumin
Herpes simplex virus
-
curcumin affects VP16-mediated recruitment of RNA polymerase II to IE gene promoters by a mechanism independent of p300/CBP histone acetyltransferase activity
curcumin
-
increase in eNOS mRNA, caused by shear stress, is completely blocked by p300 small interfering RNA; increase in eNOS mRNA, caused by shear stress, is completely blocked by pharmacological inhibition of p300/HAT activity with curcumin
curcumin
-
25 microM inhibit histidine-tagged recombinant p300 with purified human HeLa core histone as substrate by about 75%
curcumin
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
desulfo-coenzyme A
-
dead-end inhibitor, noncompetitive versus histone H3-peptide and competitive versus actyl-CoA
desulfo-coenzyme A
-
dead-end inhibitor, competitive versus acetyl-CoA, Gcn5 protein
DNA
-
dsDNA
DNA
-
acetylation of histone H1by the enzymes PCAF and GNC5 is inhibited in vivo by complexing of H1 with DNA
DNA
-
added DNA forming complexes with the histones inhibits activity
DNA
-
in vitro, enzyme form A inhibited, enzyme form B relatively insensitive
DNA
-
enzyme form A activated by low concentrations, enzyme form B inhibited
EDTA
-
weak
EDTA
-
high concentrations
epigallocatechin-3-gallate
-
epigallocatechin-3-gallate
-
-
epigallocatechin-3-gallate
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 EGCG; EGCG; EGCG
ethyl 2-methyl-6-([5-[(prop-2-yn-1-yl)amino]pentyl]oxy)quinoline-3-carboxylate
-
-
ethyl 2-methyl-6-([5-[(prop-2-yn-1-yl)amino]pentyl]oxy)quinoline-3-carboxylate
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
ethyl 2-methylquinoline-3-carboxylate
-
effects in vivo, overview
ethyl 2-methylquinoline-3-carboxylate
-
MC1626
ethyl 2-methylquinoline-3-carboxylate
-
effects in vivo, inhibitory effect on the transcription is fully GCN5-specific, overview
Fe2+
-
-
Fe2+
-
5 mM, enzyme form B
garcinol
-
-
garcinol
-
10 microM inhibit histidine-tagged recombinant p300 with purified human HeLa core histone as substrate by about 80%
garcinol
competitive inhibitor versus both acetyl-CoA and histone, docking to the p300 HAT domain encompasses amino acid residues 1284-1673, and inhibition mechanism, overview. Also inhibits PCAF HAT activity, 90% inhibition at 0.04 mM
garcinol
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
garcinol
after induction of hind limb ischemia, blood flow recovery is impaired in both PCAF-/- mice and healthy wild type mice treated with the pharmacological PCAF inhibitor garcinol
garcinol
-
both the acetylation and induction of the inflammatory proteins in elevated glucose levels are significantly inhibited by inhibitors of histone acetyltransferase, such as garcinol and antisense against the histone acetylase, p300
garcinol
garcinaol inhibits TgGCN5b and mediates changes in the parasite transcriptome. Treatment of tachyzoites with garcinol leads to a reduction of global lysine acetylation, particularly on histone H3 and TgGCN5b itself
garcinol
isolated from Garcinia indica, inhibits GCN5-mediated lysine acetyltransferase activity and prevents the replication of the parasite. Treatment of tachyzoites with garcinol leads to a reduction of global lysine acetylation, particularly on histone H3 and TgGCN5b itself. transcriptome sequencing (RNA-seq), which reveals increasing aberrant gene expression coincident with increasing concentrations of garcinol. The majority of the genes that are most significantly affected by garcinol are also associated with TgGCN5b in a previously reported chromatin immunoprecipitation assay with microarray technology analysis. The dysregulated gene expression induced by garcinol significantly inhibits Toxoplasma tachyzoite replication, and the concentrations used exhibit no overt toxicity on human host cells. Garcinol also reduces autoacetylation of TgGCN5b, garcinol treatment results in a 65% reduction in the acetylation level of HA-tagged TgGCN5b. Garcinol-mediated changes in the parasite transcriptome, overview
H3-CoA-20
-
-
H3-CoA-20
-
IC50: 0.034-0.064 mM
histone
-
histone H1 acetylation is inhibited by all other histone fractions
histone
-
histones H2A, H2B, and H3
histone
-
inhibits spermidine acetylation, enzyme forms A and B
iodoacetamide
-
enzyme form A is more sensitive than enzyme form B
isogarcinol
-
10 microM inhibit histidine-tagged recombinant p300 with purified human HeLa core histone as substrate by about 70%
isogarcinol
competitive inhibitor versus both acetyl-CoA and histone, docking to the p300 HAT domain encompasses amino acid residues 1284-1673, and inhibition mechanism, overview. Also inhibits PCAF HAT activity to maximally 50%
isogarcinol
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
isothiazolone
-
-
isothiazolone
-
binds irreversibly to proteins via thiol interactions
K+
-
strong
K+
-
175 mM: 50% inhibition
LTK14
-
20 microM inhibit histidine-tagged recombinant p300 with purified human HeLa core histone as substrate by about 70%
LTK14
noncompetitive inhibitor versus both acetyl-CoA and histone, docking to the p300 HAT domain encompasses amino acid residues 1284-1673, and inhibition mechanism, overview
Lys-CoA
-
autoacetylation IC50: 100 nM, below
Lys-CoA
-
IC50: 310-420 nM
Lys-CoA
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
MB-3
-
-
MB-3
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 an alpha-methylene-gamma-butyrolactone, shows reversible, noncovalent mode of inhibition; an alpha-methylene-gamma-butyrolactone, shows reversible, noncovalent mode of inhibition
methyl 3-(5-chloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
-
methyl 3-(5-chloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
MG149
complete inhibition at 0.05 mM
Mg2+
-
-
Mg2+
-
Mg2+ or Ca2+ required at low concentration, 5 mM, inhibition at 10-20 mM
Mg2+
-
37 mM: 50% inhibition
Mn2+
-
-
N'-(3-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyrimidin-5-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyrimidin-5-yl)benzoyl)benzenesulfonohydrazide
-
N'-(benzenesulfonyl)-4-fluoro-5-methyl[1,1'-biphenyl]-3-carbohydrazide
-
WM-8014
N'-(benzenesulfonyl)-4-fluoro-5-methyl[1,1'-biphenyl]-3-carbohydrazide
-
N-(4-[[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]benzoyl)-L-glutamic acid
-
-
N-(4-[[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]benzoyl)-L-glutamic acid
ZINC19217280
N-ethylmaleimide
-
enzyme form A is more sensitive than enzyme form B
N-[(4-fluorophenyl)methyl]-2-[(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-[1,3]oxazolidin]-3'-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide
-
A-485
N-[(4-fluorophenyl)methyl]-2-[(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-[1,3]oxazolidin]-3'-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide
-
Na+
-
strong
Na+
-
competitive against both acetyl-CoA and histones
Na+
-
160 mM: 50% inhibition
NU9056
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
NU9056
causes decreased acetylation level of histone H4 in mammalian cells
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
strongly inhibits activity of enzyme form B, formation of acyl-enzyme complex
p-chloromercuribenzoate
-
enzyme form B less sensitive than enzyme form A
Plumbagin
-
RTK1, naturally occurring hydroxynaphthoquinone, isolated from Plumbago rosea roots, inhibits histone acetylation, and induces apoptosis at higher concentrations, it inhibits p300/CBP-mediated acetylation of p53 lysine 373 non-competitively, 25 microM inhibit histidine-tagged recombinant p300 with purified human HeLa core histone as substrate by about 60% compared to control; RTK1, naturally occurring hydroxynaphthoquinone, isolated from Plumbago rosea roots, it does not inhibit PCAF acetylation of p53 lysine 320 in vivo in HEK-293 cells (pretreated with acetylation inducer doxorubicin), but 10, 25, and 50 microM inhibit FLAG-tagged recombinant PCAF in vitro (30°C) with purified human HeLa core histone as substrate
Plumbagin
O15516, O95251, P21675, Q15788, Q8WYB5, Q92793, Q92794, Q92830, Q92831, Q92993, Q9BQG0, Q9H7Z6, Q9H9T3, Q9UKN8, Q9Y6Q9 -
Plumbagin
-
RTK1, naturally occurring hydroxynaphthoquinone, isolated from Plumbago rosea roots
protein HBZ
HTLV-1 (basic zipper factor, from a human T cell leukemia virus), interacts with HBO1 during pathogenesis and inhibits its acetylation activity to reduce p53-mediated transcription activation of p21/CDKN1A and Gadd45a, and subsequently delays G2-cell cycle arrest. BRPF2 binds to HBO1 on the hinge connecting the NTD and MYST domain, thus it is reasonable to develop BRPF2-mimic peptides or molecules for disrupting HBO1-BRPF2 interaction and subsequently prevent the binding of HBO1 to chromatin
-
protein HBZ
HTLV-1 (basic zipper factor, from a human T cell leukemia virus), interacts with HBO1 during pathogenesis and inhibits its acetylation activity to reduce p53-mediated transcription activation of p21/CDKN1A and Gadd45a, and subsequently delays G2-cell cycle arrest
-
Triton X-100
-
-
Triton X-100
-
no inhibition
Zn2+
-
-
Zn2+
-
5 mM, enzyme form B
[histone H4]-L-lysine16-CoA
bisubstrate inhibitor, i.e. Ac-SGRGKGGKGLGKGGAK(CoA)RHRK
-
[histone H4]-L-lysine16-CoA
-
-
-
additional information
-
monovalent cations cause a 50% decrease in activity at an average concentration of 51 mM, divalent cations at 15 mM
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
-
screening for small molecule inhibitors reducing the cell growth, overview
-
additional information
-
inhibitory potency of N-substituted isothiazolone-based compounds, in vivo cell proliferation inhibition, overview
-
additional information
-
although downregulation of UHRF1 by RNA interference enhances Tip60 expression, a significant decrease of the level of acetylated H2AK5 is observed
-
additional information
-
relative inhibition of p300, CBP, GCN5, and PCAF, overview
-
additional information
5-chloroisothiazoline inhibitors: design, synthesis and study of inhibitory potencies and inhibition of cell growth, molecular modeling, overview; N-methyl-5-chloroisothiazolone/N-methylisothiazolone in a ratio of 3:1 in Kathon TM CG, a preservative in cosmetics, that inhibits PCAF and the growth of cell lines A2780 and HEK-293
-
additional information
-
inhibitory potencies of isothiazolones and isothiazolone-1-oxides on PCAF and growth inhibition of Hep-G2 cancer cells, overview
-
additional information
-
HBO1 dissociation from origins is either triggered by proteolytic degradation of a key licensing cofactor or by post-translational event(s) induced by HU and/or actinomycin D treatment(s)
-
additional information
-
no inhibition of p300 by 5-methoxy-2-methyl-1,4-naphthoquinone (RTK2, alkyl substitution of hydroxyl group), 5-ethoxy-2-methyl-1,4-naphthoquinone (RTK3, alkyl substitution of hydroxyl group), 5-isopropoxy-2-methyl-1,4-naphthoquinone (RTK4, alkyl substitution of hydroxyl group), and 5-[2-(dimethylamino)-ethoxy]-2-methyl-1,4-naphthoquinone (RTK10, N,N-dimethylamine substitution of hydroxyl group), less than 10% inhibition with 6-methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl acetate (RTK5, acetyl substitution of hydroxyl group), 6-methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl methanesulfonate (RTK6, sulfonyl substitution of hydroxyl group), 2-methyl-5-(2-piperidin-1-ylethoxy)-1,4-naphthoquinone (RTK7, piperidine substitution of hydroxyl group), 2-methyl-5-(2-morpholin-4-ylethoxy)-1,4-naphthoquinone (RTK8, morpholine substitution of hydroxyl group), and ethyl [(6-methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl)-oxy]acetate (RTK9, ester substitution of hydroxyl group)
-
additional information
effect of garcinol and its derivative on PCAF stability, overview. Isothermal titration calorimetry studies and molecular mechanisms of p300 HAT inhibition by specific and nonspecific HAT inhibitors: garcinol, isogarcinol. Residues LTK14, S1396, Y1397, G1626, and R1627 contact the inhibitors, overview
-
additional information
-
synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors active both in vitro and in vivo, overview
-
additional information
no inhibition by 14, 11c, 13, 8a, and 8b; no inhibition by 2-hydroxy-5-pentylbenzoic acid, 2-hydroxy-6-(5-hydroxypentyl)benzoic acid, and (4E)-2-(4-acetylphenyl)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
additional information
no inhibition by 14, 11c, 13, 8a, and 8b; no inhibition by 2-hydroxy-5-pentylbenzoic acid, 2-hydroxy-6-(5-hydroxypentyl)benzoic acid, and (4E)-2-(4-acetylphenyl)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
additional information
some (thiazol-2-yl)hydrazones act as antiprotozoal, antifungal and anti-MAO agents and as well as Gcn5 HAT inhibitors
-
additional information
-
some (thiazol-2-yl)hydrazones act as antiprotozoal, antifungal and anti-MAO agents and as well as Gcn5 HAT inhibitors
-
additional information
docking of C646 and C646-yne to a structure of p300 (PDB: 3BIY) suggests the two molecules can adopt a similar conformation in the KAT active site
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
-
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview. No inhibition by PU141
-
additional information
-
the enzyme is not inhibited by xyloside-primed GAG chains
-
additional information
high-throughput screening to discover inhibitors of histone acetyltransferase KAT6A, synthesis, and structure-activity relationship analysis, inhibition parameters and bioavailability, overview
-
additional information
-
design, synthesis and evaluation of a set of substrate-based peptide inhibitors containing multiple binding modalities, overview. In addition to the CoA moiety and the histone H3 peptide backbone, mono- and tri-methyl marks are incorporated at Lys4 and/or Lys9 sites in the H3 peptide substrate. The biochemical assay results show that the presence of methyl group(s) on the substrate results in more potent inhibitors of Tip60, relative to the parent H3-CoA bisubstrate inhibitor, inhibitory properties of the ligands against full-length Tip60 and the HAT domain, the K4me1 and K9me3 marks contribute to the potency augmentation by interacting with the catalytic region of the enzyme. No inhibition by Ac-ARTK(me)QTARKSTGGK(Br)APRKQL, Ac-ARTKQTARKSTGGK(Sme)APRKQL and Ac-ARTKQTARK(me)3STGGK(CoA)APRKQL
-
additional information
-
PPARgamma suppresses eotaxin, an NF-kappaB target, gene expression by direct inhibition of p65-associated HAT activity, for example, by competing with p65 for limited amounts of CBP and/or by recruiting HDAC to the p65-HAT complex
-
additional information
-
both the acetylation and induction of the inflammatory proteins in elevated glucose levels are significantly inhibited by inhibitors of histone acetyltransferase, such as garcinol and antisense against the histone acetylase, p300
-
additional information
-
screening for small molecule inhibitors reducing the cell growth, overview
-
additional information
-
protein factors such as E1A and Nap1 can modulate p300/CBP HAT activity
-
additional information
-
synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors active both in vitro and in vivo, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview; analysis of KATi, bisubstrate analogues, natural compounds and synthetic derivatives, mechanism of action, structure-activity relationships, and pharmacokinetic/pharmacodynamic properties, overview
-
additional information
-
effects of three monofluorinated phenylalanine analogs p-fluorophenylalanine, m-fluorophenylalanine, and o-fluorophenylalanine on the stability and enzymatic activity of tGCN5, overview
-